Pharmacological modulation of leukotriene D4 attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome

European Journal of Pharmacology

Volumn 598, Issue 1-3, 2008, Pages 51-56

  Rehni, Ashish K ^a   Singh, Inderbir ^a   Singh, Nirmal ^b   Bansal, Nitin ^c   Bansal, Seema ^c   Kumar, Manoj ^a  

^a CHITKARA UNIVERSITY   (India)

^b PUNJABI UNIVERSITY   (India)

^c Rajendra Institute of Technology and Sciences   (India)

Author keywords

1,2,3,4,tetrahydroisoquinoline; Gamma glutamyl transpeptidase; Leukotriene D4 receptors; Montelukast sodium; Morphine dependence; Withdrawal syndrome

Indexed keywords

LEUKOTRIENE D4; MONTELUKAST; MORPHINE; NALOXONE; TETRAHYDROISOQUINOLINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; IMMUNOMODULATION; LOCOMOTION; MALE; MORPHINE ADDICTION; MOUSE; MOUSE STRAIN; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SCORING SYSTEM; WITHDRAWAL SYNDROME;

ACETATES; ANIMALS; FEMALE; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; MALE; MICE; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PAIN THRESHOLD; QUINOLINES; SIGNAL TRANSDUCTION; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROISOQUINOLINES;

EID: 54149095726     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.09.025     Document Type: Article

References (43)

1. Akil, H., Lewis, J.W., 1987. Neurotransmitters and pain control. In Akil, H., Lewis, J.W. (Eds.), Pain and Headache. Vol. 9. Basil, Karger, pp. 129-159.
2. Bernstrom K., and Hammarstrom S. Metabolism of leukotriene D by porcine kidney. J. Biol. Chem. 256 (1981) 9579-9582
3. Borgeat P., Hamberg M., and Samuelsson B. Transformation of arachidonic acid and homo-y-linolenic acid by rabbit polymorphonuclear leukocytes. J. Biol. Chem. 251 (1976) 7816-7820
4. Borgeat P., and Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc. Natl. Acad. Sci. USA. 76 (1979) 3213-3217
5. Borgeat P., and Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc. Natl. Acad. Sci. USA. 76 (1979) 2148-2152
6. Capasso A., and Sorretino L. Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea pig isolated ileum. Eur. J. Pharmacol. 330 (1997) 199-204
7. Corey E.J., Marfat A., Goto G., and Brion F. Leukotriene B. Total synthesis and assignment of stereochemistry. J. Am. Chem. Soc. 102 (1980) 7984-7985
8. D'Amour F.E., and Smith D.L. A method for determining loss of pain sensation. J. Phamacol. Exp. Ther. 72 (1941) 74-79
9. Falls W.A., and Kelsey J.E. Procedures that produce context-specific tolerance to morphine in rats also produce context-specific withdrawal. Behav. Neurosci. 103 (1989) 842-849
10. Georgescu D., Zachariou V., Barrot M., Mieda M., Willie J.T., Eisch A.J., Yanagisawa M., Nestler E.J., and DiLeone R.J. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J. Neurosci 23 (2003) 3106-3111
11. Glick S.D., and Morihisa J.M. Changes in sensitivity of morphine-induced circling behaviour after chronic treatment and persistence after withdrawal in rats. Nature 260 (1976) 159-161
12. Hardman J.G., Limbird L.E., and Gilman A.G. Drug addiction and drug abuse. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (2001), McGraw Hill, New York 631-634
13. Ichiyama T., Kajimoto M., Hasegawa M., Hashimoto K., Matsubara T., and Furukawa S. Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clin. Exp. Allergy 37 (2007) 608-614
14. Inoue M., Mishina M., and Ueda H. Locus specific rescue of GluR-1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. J. Neurosci. 23 (2003) 6529-6536
15. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 73 (1995) 191-201
16. Krantz M.J., and Mehler P.S. Treating opioid dependence growing implications for primary care. Arch. Intern. Med. 164 (2004) 277-288
17. 4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 5 (1995) 283-288
18. Lee S., Rosenberg C.R., and Musacchio M. Cross-dependence to opioid and a2-adrenergic receptor agonists in NG1O8-15 cells. FASEB J. 2 (1987) 52-55
19. 4 immunoreactivity). Proc. Nati. Acad. Sci. 81 (1984) 6212-6216
20. Liu Z., Zheng J.F., Yang L.Q., Yi L., and Hu B. Effects of sinomenine on NO/nNOS system in cerebellum and spinal cord of morphine-dependent and withdrawal mice. Sheng. Li. Xue. Bao. 59 (2007) 285-292
21. Lorenc-Koci E., Sokolowska M., and Wlodek L. Effect of acute administration of 1,2,3,4-tetrahydroisoquinoline on the levels of glutathione and reactive oxygen species, and on the enzymatic activity of gamma-glutamyl transpeptidase in dopaminergic structures of rat brain. Neuroscience 108 3 (2001) 413-420
22. Lorenc-Koci E., Sokołowska M., Kwiecień I., and Włodek L. Treatment with 1,2,3,4-tetrahydroisoquinolone affects the levels of nitric oxide, S-nitrosothiols, glutathione and the enzymatic activity of gamma-glutamyl transpeptidase in the dopaminergic structures of rat brain. Brain Res. 1049 2 (2005) 133-146
23. Marshall J., and Graham-Smith D.G. Evidence against a role of brain 5-hydroxytryptamine in the development of physical dependence upon morphine in mice. J. Pharmacol. Exp. Ther. 173 (1971) 634-641
24. 4 in human renal mesangial cells. differential activation of map kinases through distinct receptors. J. Biol. Chem 36 (2000) 27566-27575
25. 4. Mol. Pharmacol. 32 (1987) 223-229
26. Morris H.R., Taylor G.W., Piper P.J., and Tippins J.R. Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature (London) 285 (1980) 104-106
27. Murphy R.C., Hammarstrom S., and Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. USA 76 (1979) 4275-4279
28. Orning L., and Hammarstrom S. Inhibition of leukotriene C and leukotriene D biosynthesis. J. Biol. Chem. 255 (1980) 8023-8026
29. Patkina N.A., and Zvartau E.E. Rat behavior in an "open field" when chronically administered morphine. Farmakol. Toksikol. 41 (1978) 537-541
30. Reddy D.S., and Kulkarni S.K. Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging and dizocilpine-induced learning impairment. Brain Res. 799 (1998) 215-229
31. Rehni, A.K., Bhateja, P., Singh, T.G., Singh, N., In Press. Nuclear factor-κ-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone induced opioid withdrawal syndrome. Behav. Pharmacol.
32. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983) 568-575
33. Sautebin L., Spagnuolo C., Galli C., and Galli G. A mass fragmentographic procedure for the simultaneous determination of HETE and PGF2alpha in the central nervous system. Prostaglandins 16 (1978) 985-988
34. Shaw-Lutchman T.Z., Barrot M., Wallace T., Gilden L., Zachariou V., Impey S., Duman R.S., Storm D., and Nestler E.J. Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone precipitated morphine withdrawal. J. Neurosci. 22 (2002) 3663-3672
35. Spagnuolo C., Sautebin L., Galli G., Racegui G., Galli C., Mazzani S., and Ginesso M. PGF2 alpha, thromboxane B2 and HETE levels in gerbil brain cortex after ligation of common carotid arteries and decapitation. Prostaglandins 18 (1979) 53-61
36. Thompson C., Cloutier A., Bossé Y., Thivierge M., Gouill C.L., Larivée P., McDonald P.P., Stankova J., and Rola-Pleszczynski M. CysLT1 receptor engagement induces activator protein-1- and NF-kappaB-dependent IL-8 expression. Am. J. Respir. Cell Mol. Biol. 35 (2006) 697-704
37. Trang T., Sutak M., Quirion R., and Jhamandas K. Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal. Br. J. Pharmacol. 140 2 (2003) 295-304
38. Van Ree J.M., Gerrits M.A.F.M., and Vanderschuren L.J.M.J. Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol. Rev. 51 (1999) 341-396
39. 4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expression. Biochem. Biophys. Res. Commun. 350 (2006) 399-404
40. Way E.L., Loh H.H., and Shen F.H. Simultaneous quantitative assessment of morphine tolerance and physical dependence. J. Pharmacol. Exp. Ther. 167 (1969) 1-8
41. Wei E.Q., and Chen Z. Implication of 5-lipoxygenase/cysteinyl leukotriene receptors and histamine/histamine receptors in brain disease. Zhejiang Da Xue Xue Bao Yi Xue Ban 36 (2007) 105-110
42. Williams J.T., Christie M.J., and Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81 (2001) 299-343
43. Zhang Y.J., Zhang L., Ye Y.L., Fang S.H., Zhou Y., Zhang W.P., Lu Y.B., and Wei E.Q. Cysteinyl leukotriene receptors CysLT1 and CysLT2 are upregulated in acute neuronal injury after focal cerebral ischemia in mice. Acta Pharmacol. Sin. 27 (2006) 1553-1560